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Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report 
molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and 
DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of 
somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically 
significantly mutated, including RIT1 activating mutations and newly described loss-of-function 
MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations 
were more frequent in female patients, whereas mutations in RBM10 were more common in 
males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in 
samples otherwise lacking an activated oncogene, suggesting a driver role for these events in 
certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations 
driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. 
MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known 
mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway 
activation. These data establish a foundation for classification and further investigations of lung 
adenocarcinoma molecular pathogenesis.
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Lung cancer is the most common cause of global cancer-related mortality, leading to over a 
million deaths each year and adenocarcinoma is its most common histological type. 
Smoking is the major cause of lung adenocarcinoma but, as smoking rates decrease, 
proportionally more cases occur in never-smokers (defined as less than 100 cigarettes in a 
life-time). Recently, molecularly targeted therapies have dramatically improved treatment 
for patients whose tumours harbour somatically activated oncogenessuch as mutant EGFR1 
or translocated ALK, RET, orROS1 (refs 2–4). Mutant BRAF and ERBB2 (ref. 5) are also 
investigational targets. However, mostlung adenocarcinomas either lack an identifiable 
driver oncogene, or harbour mutations in KRAS and are therefore still treated with 
conventional chemotherapy. Tumour suppressor gene abnormalities, such as those in TP53 
(ref. 6), STK11 (ref. 7), CDKN2A8, KEAP1 (ref. 9), and SMARCA4 (ref. 10) are also 
common but are not currently clinically actionable. Finally, lung adenocarcinoma shows 
high rates of somatic mutation and genomic rearrangement, challenging identification of all 
but the most frequent driver gene alterations because of a large burden of passenger events 
per tumour genome11–13. Our efforts focused on comprehensive, multiplatform analysis of 
lung adenocarcinoma, with attention towards pathobiology and clinically actionable events.
Clinical samples and histopathologic data
We analysed tumour and matched normal material from 230 previously untreated lung 
adenocarcinoma patients who provided informed consent (Supplementary Table 1). All 
major histologic types of lung adenocarcinoma were represented: 5% lepidic, 33% acinar, 
9% papillary, 14% micropapillary, 25% solid, 4% invasive mucinous, 0.4% colloid and 8% 
unclassifiable adenocarcinoma (Supplementary Fig. 1)14. Median follow-up was 19 months, 
and 163 patients were alive at the time of last follow-up. Eighty-one percent of patients 
reported pastor present smoking. Supplementary Table 2 summarizes demographics. DNA, 
RNA and protein were extracted from specimens and quality-control assessments were 
performed as described previously15. Supplementary Table 3 summarizes molecular 
estimates of tumour cellularity16.
Somatically acquired DNA alterations
We performed whole-exome sequencing (WES) on tumour and germ-line DNA, with a 
mean coverage of 97.6× and 95.8×, respectively, as performed previously17. The mean 
somatic mutation rate across the TCGA cohort was 8.87 mutations per megabase (Mb) of 
DNA (range: 0.5–48, median: 5.78). The non-synonymous mutation rate was 6.86 per Mb. 
MutSig2CV18 identified significantly mutated genes among our 230 cases along with 182 
similarly-sequenced, previously reported lung adenocarcinomas12. Analysis of these 412 
tumour/normal pairs highlighted 18 statistically significant mutated genes (Fig. 1 a shows 
co-mutation plot of TCGA samples (n =230), Supplementary Fig. 2 shows co-mutation plot 
of all samples used in the statistical analysis (n =412) and Supplementary Table 4 contains 
complete MutSig2CV results, which also appear on the TCGA Data Portal along with many 
associated data files (https://tcga-data.nci.nih.gov/docs/publications/luad_2014/). TP53 was 
commonly mutated (46%). Mutations in KRAS (33%) were mutually exclusive with those in 
EGFR (14%). BRAF was also commonly mutated (10%), as were PIK3CA (7%), MET (7%) 
and the small GTPase gene, RIT1 (2%). Mutations in tumour suppressor genes including 
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STK11 (17%), KEAP1 (17%), NF1 (11%), RB1 (4%) and CDKN2A (4%) were observed. 
Mutations in chromatin modifying genes SETD2(9%), ARID1A(7%) and SMARCA4 (6%) 
and the RNA splicing genes RBM10 (8%) and U2AF1 (3%) were also common. Recurrent 
mutations in the MGA gene (which encodes a Max-interacting protein on the MYC 
pathway19) occurred in 8% of samples. Loss-of-function (frameshift and nonsense) 
mutations in MGA were mutually exclusive with focal MYC amplification (Fisher’s exact 
test P =0.04), suggesting a hitherto unappreciated potential mechanism of MYC pathway 
activation. Coding single nucleotide variants and indel variants were verified by 
resequencing at a rate of 99% and 100%, respectively (Supplementary Fig. 3a, 
Supplementary Table 5). Tumour purity was not associated with the presence of false 
negatives identified in the validation data (P =0.31; Supplementary Fig. 3b).
Past or present smoking associated with cytosine to adenine (C >A) nucleotide transversions 
as previously described both in individual genes and genome-wide12,13. C >A nucleotide 
transversion fraction showed two peaks; this fraction correlated with total mutation count 
(R2 =0.30) and inversely correlated with cytosine to thymine (C >T) transition frequency (R2 
=0.75) (Supplementary Fig. 4). We classified each sample (Supplementary Methods) into 
one of two groups named transversion-high (TH, n =269), and transversion-low (TL, n 
=144). The transversion-high group was strongly associated with past or present smoking (P 
< 2.2 ×10−16), consistent with previous reports13. The transversion-high and transversion-
low patient cohorts harboured different gene mutations. Whereas KRAS mutations were 
significantly enriched in the transversion-highcohort (P=2.1×10−13), EGFR mutations were 
significantly enriched in the transversion-low group (P =3.3 ×10−6). PIK3CA and RB1 
mutations were likewise enriched in transversion-low tumours (P <0.05). Additionally, the 
transversion-low tumours were specifically enriched for in-frame insertions in EGFR and 
ERBB2 (ref. 5) and for frameshift indels in RB1 (Fig. 1b). RB1 is commonly mutated in 
small-cell lung carcinoma (SCLC). We found RB1 mutations in transversion-low 
adenocarcinomas were enriched for frameshift indels versus single nucleotide substitutions 
compared to SCLC (P <0.05)20,21 suggesting a mutational mechanism in transversion-low 
adenocarcinoma that is probably distinct from smoking in SCLC.
Gender is correlated with mutation patterns in lung adenocarcinoma22. Only a fraction of 
significantly mutated genes from the complete set reported in this study (Fig. 1a) were 
enriched in men or women (Fig. 1c). EGFR mutations were enriched in tumours from the 
female cohort (P =0.03) whereas loss-of-function mutations within RBM10, an RNA-
binding protein located on the X chromosome23 were enriched in tumours from men (P 
=0.002). When examining the transversion-high group, 16 out of 21 RBM10 mutations were 
observed in males (P =0.003, Fisher’s exact test).
Somatic copy number alterations were very similar to those previously reported for lung 
adenocarcinoma24 (Supplementary Fig. 5, Supplementary Table 6). Significant 
amplifications included NKX2-1, TERT, MDM2, KRAS, EGFR, MET, CCNE1, CCND1, 
TERC and MECOM (Supplementary Table 6), as previously described24, 8q24 near MYC, 
and a novel peak containing CCND3 (Supplementary Table 6). The CDKN2A locus was the 
most significant deletion (Supplementary Table 6). Supplementary Table 7 summarizes 
molecular and clinical characteristics by sample. Low-pass whole-genome sequencing on a 
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subset (n =93) of the samples revealed an average of 36 gene–gene and gene–inter-gene 
rearrangements per tumour. Chromothripsis25 occurred in six of the 93 samples (6%) 
(Supplementary Fig. 6, Supplementary Table 8). Low-pass whole genome sequencing-
detected rearrangements appear in Supplementary Table 9.
Description of aberrant RNA transcripts
Gene fusions, splice site mutations or mutations in genes encoding splicing factors promote 
or sustain the malignant phenotype by generating aberrant RNA transcripts. Combining 
DNA with mRNA sequencing enabled us to catalogue aberrant RNA transcripts and, in 
many cases, to identify the DNA-encoded mechanism for the aberration. Seventy-five per 
cent of somatic mutations identified by WES were present in the RNA transcriptome when 
the locus in question was expressed (minimum 5×) (Supplementary Fig. 7a) similar to prior 
analyses15. Previously identified fusions involving ALK (3/230 cases), ROS1 (4/230) and 
RET (2/230) (Fig. 2a, Supplementary Table 10), all occurred in transversion-low tumours (P 
=1.85 × 10−4, Fisher’s exact test).
MET activation can occur by exon 14 skipping, which results in a stabilized protein26. Ten 
tumours had somatic MET DNA alterations with MET exon 14 skipping in RNA. In nine of 
these samples, a 5′ or 3′ splice site mutation or deletion was identified27. MET exon 14 
skipping was also found in the setting of a MET Y1003* stop codon mutation (Fig. 2b, 
Supplementary Fig. 8a). The codon affected by the Y1003* mutation is predicted to disrupt 
multiple splicing enhancer sequences, but the mechanism of skipping remains unknown in 
this case.
S34F mutations in U2AF1 have recently been reported in lung adenocarcinoma12 but their 
contribution to oncogenesis remains unknown. Eight samples harboured U2AF1S34F. We 
identified 129 splicing events strongly associated with U2AF1S34F mutation, consistent with 
the role of U2AF1 in 3′-splice site selection28. Cassette exons and alternative 3′ splice sites 
were most commonly affected (Fig. 2c, Supplementary Table 11)29. Among these events, 
alternative splicing of the CTNNB1 protooncogene was strongly associated with U2AF1 
mutations (Supplementary Fig. 8b). Thus, concurrent analysis of DNA and RNA enabled 
delineation of both cis and trans mechanisms governing RNA processing in lung 
adenocarcinoma.
Candidate driver genes
The receptor tyrosine kinase (RTK)/RAS/RAF pathway is frequently mutated in lung 
adenocarcinoma. Striking therapeutic responses are often achieved when mutant pathway 
components are successfully inhibited. Sixty-two percent (143/230) of tumours harboured 
known activating mutations in known driver oncogenes, as defined by others30. Cancer-
associated mutations in KRAS (32%, n =74), EGFR (11%, n =26) and BRAF (7%, n =16) 
were common. Additional, previously uncharacterized KRAS, EGFR and BRAF mutations 
were observed, but were not classified as driver oncogenes for the purposes of our analyses 
(see Supplementary Fig. 9a for depiction of all mutations of known and unknown 
significance); explaining the differing mutation frequencies in each gene between this 
analysis and the overall mutational analysis described above. We also identified known 
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activating ERBB2 in-frame insertion and point mutations (n =5)6, as well as mutations in 
MAP2K1 (n =2), NRAS and HRAS (n =1 each). RNA sequencing revealed the 
aforementioned MET exon 14 skipping (n =10) and fusions involving ROS1 (n =4), ALK (n 
=3) and RET (n =2). We considered these tumours collectively as oncogene-positive, as they 
harboured a known activating RTK/RAS/ RAF pathway somatic event. DNA amplification 
events were not considered to be driver events before the comparisons described below.
We sought to nominate previously unrecognized genomic events that might activate this 
critical pathway in the 38% of samples without a RTK/RAS/RAF oncogene mutation. 
Tumour cellularity did not differ between oncogene-negative and oncogene-positive samples 
(Supplementary Fig. 9b). Analysis of copy number alterations using GISTIC31 identified 
unique focal ERBB2 and MET amplifications in the oncogene-negative subset (Fig. 3a, 
Supplementary Table 6); amplifications in other wild-type proto-oncogenes, including KRAS 
and EGFR, were not significantly different between the two groups.
We next analysed WES data independently in the oncogene-negative and oncogene-positive 
subsets. We found that TP53, KEAP1, NF1 and RIT1 mutations were significantly enriched 
in oncogene-negative tumours (P <0.01; Fig. 3b, Supplementary Table 12). NF1 mutations 
have previously been reported in lung adenocarcinoma11, but this is the first study, to our 
knowledge, capable of identifying all classes of loss-of-function NF1 defects and to 
statistically demonstrate that NF1 mutations, as well as KEAP1 and TP53 mutations are 
enriched in the oncogene-negative subset of lung adenocarcinomas (Fig. 3c). All RIT1 
mutations occurred in the oncogene-negative subset and clustered around residue Q79 
(homologous to Q61 in the switch II region of RAS genes). These mutations transform 
NIH3T3 cells and activate MAPK and PI(3)K signalling32, supporting a driver role for 
mutant RIT1 in 2% of lung adenocarcinomas. This analysis increases the rate at which 
putative somatic lung adenocarcinoma driver events can be identified within the 
RTK/RAS/RAF pathway to 76% (Fig. 3d).
Recurrent alterations in key pathways
Recurrent aberrations in multiple key pathways and processes characterize lung 
adenocarcinoma (Fig. 4a). Among these were RTK/RAS/ RAF pathway activation (76% of 
cases), PI(3)K-mTOR pathway activation (25%), p53 pathway alteration (63%), alteration of 
cell cycle regulators (64%, Supplementary Fig. 10), alteration of oxidative stress pathways 
(22%, Supplementary Fig. 11), and mutation of various chromatin and RNA splicing factors 
(49%).
We then examined the phenotypic sequelae of some key genomic events in the tumours in 
which they occurred. Reverse-phase protein arrays provided proteomic and 
phosphoproteomic phenotypic evidence of pathway activity. Antibodies on this platform are 
listed in Supplementary Table 13. This analysis suggested that DNA sequencing did not 
identify all samples with phosphoprotein evidence of activation of a given signalling 
pathway. For example, whereas KRAS-mutant lung adenocarcinomas had higher levels of 
phosphorylated MAPK than KRAS wild-type tumours had on average, many KRAS wild-
type tumours displayed significant MAPK pathway activation (Fig. 4b, Supplementary Fig. 
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10). The multiple mechanisms by which lung adenocarcinomas achieve MAPK activation 
suggest additional, still undetected RTK/RAS/ RAF pathway alterations. Similarly, we 
found significant activation of mTOR and its effectors (p70S6kinase, S6, 4E-BP1) in a 
substantial fraction of the tumours (Fig. 4c). Analysis of mutations in PIK3CA and STK11, 
STK11 protein levels, and AMPK and AKT phosphorylation33 led to the identification of 
three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal 
mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by 
either STK11-inactivating mutation or combined low STK11 expression and low AMPK 
activation and (3) tumours showing high mTOR activity accompanied by either 
phosphorylated AKT activation, PIK3CA mutation, or both. As with MAPK, many tumours 
lack an obvious underlying genomic alteration to explain their apparent mTOR activation.
Molecular subtypes of lung adenocarcinoma
Broad transcriptional and epigenetic profiling can reveal downstream consequences of 
driver mutations, provide clinically relevant classification and offer insight into tumours 
lacking clear drivers. Prior unsupervised analyses of lung adenocarcinoma gene expression 
have used varying nomenclature for transcriptional subtypes of the disease34–37. To 
coordinate naming of the transcriptional subtypes with the histopathological38, anatomic and 
mutational classifications of lung adenocarcinoma, we propose an updated nomenclature: 
the terminal respiratory unit (TRU, formerly bronchioid), the proximal-inflammatory (PI, 
formerly squamoid), and the proximal-proliferative (PP, formerly magnoid)39 transcriptional 
subtypes (Fig. 5a). Previously reported associations of expression signatures with pathways 
and clinical outcomes34,36,39 were observed (Supplementary Fig. 7b) and integration with 
multi-analyte data revealed statistically significant genomic alterations associated with these 
transcriptional subtypes. The PP subtype was enriched for mutation of KRAS, along with 
inactivation of the STK11 tumour suppressor gene by chromosomal loss, inactivating 
mutation, and reduced gene expression. In contrast, the PI subtype was characterized by 
solid histopathology and co-mutation of NF1 and TP53. Finally, the TRU subtype harboured 
the majority of the EGFR-mutated tumours as well as the kinase fusion expressing tumours. 
TRU subtype membership was prognostically favourable, as seen previously34 
(Supplementary Fig. 7c). Finally, the subtypes exhibited different mutation rates, transition 
frequencies, genomic ploidy profiles, patterns of large-scale aberration, and differed in their 
association with smoking history (Fig. 5a). Unsupervised clustering of miRNA sequencing-
derived or reverse phase protein array (RPPA)-derived data also revealed significant 
heterogeneity, partially overlapping with the mRNA-based subtypes, as demonstrated in 
Supplementary Figs 12 and 13.
Mutations in chromatin-modifying genes (for example, SMARCA4, ARID1A and SETD2) 
suggest a major role for chromatin maintenance in lung adenocarcinoma. To examine 
chromatin states in an unbiased manner, we selected the most variable DNA methylation-
specific probes in CpG island promoter regions and clustered them by methylation intensity 
(Supplementary Table 14). This analysis divided samples into two distinct subsets: a 
significantly altered CpG island methylator phenotype-high (CIMP-H(igh)) cluster and a 
more normal-like CIMP-L(ow) group, with a third set of samples occupying an intermediate 
level of methylation at CIMP sites (Fig. 5b). Our results confirm a prior report40 and provide 
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additional insights into this epigenetic program. CIMP-H tumours often showed DNA 
hypermethylation of several key genes: CDKN2A, GATA2, GATA4, GATA5, HIC1, HOXA9, 
HOXD13, RASSF1, SFRP1, SOX17 and WIF1 among others (Supplementary Fig. 14). WNT 
pathway genes are significantly over-represented in this list (P value =0.0015) suggesting 
that this is a key pathway with an important driving role within this subtype. MYC 
overexpression was significantly associated with the CIMP-H phenotype as well (P =0.003).
Although we did not find significant correlations between global DNA methylation patterns 
and individual mutations in chromatin remodelling genes, there was an intriguing 
association between SETD2 mutation and CDKN2A methylation. Tumours with low 
CDKN2A expression due to methylation (rather than due to mutation or deletion) had lower 
ploidy, fewer overall mutations (Fig. 5c) and were significantly enriched for SETD2 
mutation, suggesting an important role for this chromatin-modifying gene in the 
development of certain tumours.
Integrative clustering41 of copy number, DNA methylation and mRNA expression data 
found six clusters (Fig. 5c). Tumour ploidy and mutation rate are higher in clusters 1–3 than 
in clusters 4–6. Clusters 1–3 frequently harbour TP53 mutations and are enriched for the two 
proximal transcriptional subtypes. Fisher’s combined probability tests revealed significant 
copy number associated gene expression changes on 3q in cluster one, 8q in cluster two, and 
chromosome 7 and 15q in cluster three (Supplementary Fig. 15). The low ploidy and low 
mutation rate clusters four and five contain many TRU samples, whereas tumours in cluster 
6 have comparatively lower tumour cellularity, and few other distinguishing molecular 
features. Significant copy number-associated gene expression changes are observed on 6q in 
cluster four and 19p in cluster five. The CIMP-H tumours divided into a high ploidy, high 
mutation rate, proximal-inflammatory CIMP-H group (cluster 3) and a low ploidy, low 
mutation rate, TRU-associated CIMP-H group (cluster 4), suggesting that the CIMP 
phenotype in lung adenocarcinoma can occur in markedly different genomic and 
transcriptional contexts. Furthermore, cluster four is enriched for CDKN2A methylation and 
SETD2 mutations, suggesting an interaction between somatic mutation of 
SETD2andderegulated chromatin maintenance in this subtype. Finally, cluster membership 
was significantly associated with mutations in TP53, EGFR and STK11 (Supplementary Fig. 
15, Supplementary Table 6).
Conclusions
We assessed the mutation profiles, structural rearrangements, copy number alterations, DNA 
methylation, mRNA, miRNA and protein expression of 230 lung adenocarcinomas. In 
recent years, the treatment of lung adenocarcinoma has been advanced by the development 
of multiple therapies targeted against alterations in the RTK/RAS/RAF pathway. We 
nominate amplifications in MET and ERBB2 as well as mutations of NF1 and RIT1 as driver 
events specifically in otherwise oncogene-negative lung adenocarcinomas. This analysis 
increases the fraction of lung adenocarcinoma cases with somatic evidence of 
RTK/RAS/RAF activation from 62% to 76%. While all lung adenocarcinomas may activate 
this pathway by some mechanism, only a subset show tonic pathway activation at the protein 
level, suggesting both diversity between tumours with seemingly similar activating events 
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and as yet undescribed mechanisms of pathway activation. Therefore, the current study 
expands the range of possible targetable alterations within the RTK/RAS/RAF pathway in 
general and suggests increased implementation of MET and ERBB2/HER2 inhibitors in 
particular. Our discovery of inactivating mutations of MGA further underscores the 
importance of the MYC pathway in lung adenocarcinoma.
This study further implicates both chromatin modifications and splicing alterations in lung 
adenocarcinoma through the integration of DNA, transcriptome and methylome analysis. 
We identified alternative splicing due to both splicing factor mutations in trans and mutation 
of splice sites in cis, the latter leading to activation of the MET gene by exon 14 skipping. 
Cluster analysis separated tumours based on single-gene driver events as well as large-scale 
aberrations, emphasizing lung adenocarcinoma’s molecular heterogeneity and combinatorial 
alterations, including the identification of coincident SETD2 mutations and CDKN2A 
methylation in a subset of CIMP-H tumours, providing evidence of a somatic event 
associated with a genome-wide methylation phenotype. These studies provide new 
knowledge by illuminating modes of genomic alteration, highlighting previously 
unappreciated altered genes, and enabling further refinement in sub-classification for the 
improved personalization of treatment for this deadly disease.
METHODS SUMMARY
All specimens were obtained from patients with appropriate consent from the relevant 
institutional review board. DNA and RNA were collected from samples using the Allprep 
kit (Qiagen). We used standard approaches for capture and sequencing of exomes from 
tumour DNA and normal DNA15 and whole-genome shotgun sequencing. Significantly 
mutated genes were identified by comparing them with expectation models based on the 
exact measured rates of specific sequence lesions42. GISTIC analysis of the circular-binary-
segmented Affymetrix SNP 6.0 copy number data was used to identify recurrent 
amplification and deletion peaks31. Consensus clustering approaches were used to analyse 
mRNA, miRNA and methylation subtypes using previous approaches15. The publication 
web page is (https://tcga-data.nci.nih.gov/docs/publications/luad_2014/). Sequence files are 
in CGHub (https://cghub.ucsc.edu/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Somatic mutations in lung adenocarcinoma
a, Co-mutation plot from whole exome sequencing of 230 lung adenocarcinomas. Data from 
TCGA samples were combined with previously published data12 for statistical analysis. Co-
mutation plot for all samples used in the statistical analysis (n =412) can be found in 
Supplementary Fig. 2. Significant genes with a corrected P value less than 0.025 were 
identified using the MutSig2CV algorithm and are ranked in order of decreasing prevalence. 
b, c, The differential patterns of mutation between samples classified as transversion high 
and transversion low samples (b) or male and female patients (c) are shown for all samples 
used in the statistical analysis (n =412). Stars indicate statistical significance using the 
Fisher’s exact test (black stars: q <0.05, grey stars: P <0.05) and are adjacent to the sample 
set with the higher percentage of mutated samples.
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Figure 2. Aberrant RNA transcripts in lung adenocarcinoma associated with somatic DNA 
translocation or mutation
a, Normalized exon level RNA expression across fusion gene partners. Grey boxes around 
genes mark the regions that are removed as a consequence of the fusion. Junction points of 
the fusion events are also listed in Supplementary Table 9. Exon numbers refer to reference 
transcripts listed in Supplementary Table 9. b, MET exon 14 skipping observed in the 
presence of exon 14 splice site mutation (ss mut), splice site deletion (ss del) or a Y1003* 
mutation. A total of 22 samples had insufficient coverage around exon 14 for quantification. 
The percentage skipping is (total expression minus exon 14 expression)/total expression. c, 
Significant differences in the frequency of 129 alternative splicing events in mRNA from 
tumours with U2AF1 S34F tumours compared to U2AF1 WT tumours (q value <0.05). 
Consistent with the function of U2AF1 in 3′ splice site recognition, most splicing 
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differences involved cassette exon and alternative 3′ splice site events (chi-squared test, P 
<0.001).
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Figure 3. Identification of novel candidate driver genes
a, GISTIC analysis of focal amplifications in oncogene-negative (n =87) and oncogene-
positive (n =143) TCGA samples identifies focal gains of MET and ERBB2 that are specific 
to the oncogene-negative set (purple). b, TP53, KEAP1, NF1 and RIT1 mutations are 
significantly enriched in samples otherwise lacking oncogene mutations (adjusted P <0.05 
by Fisher’s exact test). c, Co-mutation plot of variants of known significance within the 
RTK/RAS/RAF pathway in lung adenocarcinoma. Not shown are the 63 tumours lacking an 
identifiable driver lesion. Only canonical driver events, as defined in Supplementary Fig. 9, 
and proposed driver events, are shown; hence not every alteration found is displayed. d, 
New candidate driver oncogenes (blue: 13% of cases) and known somatically activated 
drivers events (red: 63%) that activate the RTK/RAS/RAF pathway can be found in the 
majority of the 230 lung adenocarcinomas.
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Figure 4. Pathway alterations in lung adenocarcinoma
a, Somatic alterations involving key pathway components for RTK signalling, mTOR 
signalling, oxidative stress response, proliferation and cell cycle progression, nucleosome 
remodelling, histone methylation, and RNA splicing/processing. b, c, Proteomic analysis by 
RPPA (n =181) P values by two-sided t-test. Box plots represent 5%, 25%, 75%, median, 
and 95%. PP, proximal proliferative; TRU, terminal respiratory unit; PI, proximal 
inflammatory. c, mTOR signalling may be activated, by either Akt (for example, via PI(3)K) 
or inactivation of AMPK (for example, via STK11 loss). Tumours were separated into three 
main groups: those with PI(3)K-AKT activation, through either PIK3CA activating mutation 
or unknown mechanism (high p-AKT); those with LKB1-AMPK inactivation, through either 
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STK11 mutation or unknown mechanism with low levels of LKB1 and p-AMPK; and those 
showing none of the above features.
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Figure 5. Integrative analysis
a–c, Integrating unsupervised analyses of 230 lung adenocarcinomas reveals significant 
interactions between molecular subtypes. Tumours are displayed as columns, grouped by 
mRNA expression subtypes (a), DNA methylation subtypes (b), and integrated subtypes by 
iCluster analysis (c). All displayed features are significantly associated with subtypes 
depicted. The CIMP phenotype is defined by the most variable CpG island and promoter 
probes.
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